Recent extremely meaningful negative changes in investment behavior have impacted CASI Pharmaceuticals Inc (NASDAQ: CASI): negative upside/downside volume developed, and its shorter term price trend turned down.
CASI Pharmaceuticals Inc (NASDAQ: CASI) has recently experienced meaningful negative changes in fundamentals: the stock’s power rating fell below 50, and significant quarterly sales deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
CASI is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
CASI Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. CASI Pharmaceuticals has a poor Power Rating of 27 and a very low Appreciation Score of 8, with the Lowest Value Trend Rating the result.
Recent Price Action
CASI Pharmaceuticals Inc (NASDAQ: CASI) stock closed at $3.22 on 6/12/24 after a modest decline of -1.8%. Trading volume in this decline was normal. The stock has declined -9.8% during the last week and has been weak relative to the market over the last nine months.
Be the first to comment